Dr. del Campo’s main scientific interest is to understand the biological changes that underlie the different dementia types and translate this knowledge into applicable diagnostic tests and potential therapeutic targets. As translational neurobiologist, she has worked with human samples as well as different cell and animal models. She is currently co-leading highly collaborative studies analysing the proteome in different biofluids (CSF and plasma) from patients with different types of dementia (PRIDE and bPRIDE projects) to identify early and specific biomarker signatures that might be useful in clinical setting and trials. Understanding the molecular mechanisms behind those changes is also highly relevant, as it may reveal potential therapeutic targets. By combining -omics data (e.g. proteome and genome), she aims also to identify novel pathways and molecules involved in the pathogenesis of dementia.